BC Week In Review | Jan 13, 2014
Clinical News

Cevira regulatory update

Photocure said FDA denied the company's request to grant Fast Track designation to Cevira to treat HPV infection in women with cervical intraepithelial neoplasia (CIN) grade 2. Photocure said FDA's decision is based on a...
BC Week In Review | Apr 15, 2013
Clinical News

Cevira: Final Phase IIb data

Final data from a double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira improved the 6-month disease clearance rate of HPV types 16 and 18...
BC Week In Review | Dec 24, 2012
Clinical News

Cevira: Phase IIb data

A double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira non-significantly improved the 3-month disease clearance rate (73% vs. 60%, p=0.2) and the clearance rate...
BC Week In Review | Oct 8, 2012
Company News

Photocure dermatology news

Photocure said it will exit its Allumera cosmetic dermatology business in the U.S. by the end of this year because the business has not delivered the growth potential it had expected. In June 2011, Photocure...
BC Week In Review | Feb 27, 2012
Clinical News

Cevira: Completed Phase IIb enrollment

Photocure completed enrollment of 240 patients with low to moderate grade cervical intraepithelial neoplasia (CIN) in a placebo-controlled, dose-finding, U.S. and European Phase II trial evaluating intravaginal Cevira. Photocure ASA (OSE:PHO), Oslo, Norway   Product:...
BC Week In Review | Jun 27, 2011
Clinical News

Cevira: Phase II started

Photocure began a placebo-controlled, dose-finding, U.S. and European Phase II trial to evaluate intravaginal Cevira in 240 patients with low to moderate grade cervical intraepithelial neoplasia (CIN). Photocure ASA (OSE:PHO), Oslo, Norway   Product: Cevira...
BC Week In Review | Jan 31, 2011
Clinical News

Cevira: Additional Phase IIa data

Additional data from a Phase IIa trial in 70 patients with low-grade cervical lesions showed that Cevira led to a significantly greater 6-month disease clearance rate as measured by Pap smear vs. placebo (57% vs....
BC Week In Review | Oct 18, 2010
Clinical News

Cevira: Preliminary Phase II data

Preliminary data from a Phase II trial in 70 patients with mild cervical abnormalities showed that Cevira produced a 3-month disease clearance rate as measured by Pap smear of 71% vs. 43% for placebo. No...
BC Innovations | Mar 18, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Not applicable In vitro and chick embryo studies identified light-activated boron dipyrromethene compounds that could help treat cancer. In three human cancer cell lines,...
BC Week In Review | May 11, 2009
Clinical News

Cevira: Phase I/II started

PhotoCure disclosed that last quarter it began a 12-month, double-blind, placebo-controlled, European Phase I/II trial to evaluate Cevira in 70 patients. PhotoCure ASA (OSE:PHO), Oslo, Norway   Product: Cevira   Business: Cancer   Molecular target:...
Items per page:
1 - 10 of 11